Petosemtamab plus chemotherapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called petosemtamab combined with chemotherapy for people with advanced colorectal cancer that has not responded to one prior treatment. The trial aims to see if adding petosemtamab helps the cancer shrink or grow more slowly compared to adding a standard targeted therapy like cetuximab or bevacizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that is advanced (has spread or cannot be removed by surgery).
- Your tumor must test negative for KRAS, NRAS, and BRAF mutations (called 'wild type').
- You must have had no more than one previous treatment for advanced disease, and that treatment must have included a standard chemotherapy combination (like FOLFOX or FOLFIRI).
- You must not have been treated with drugs that target EGFR (such as cetuximab or panitumumab) before.
- You must not have a known deficiency in the DPD enzyme or certain genetic variants that affect how your body handles chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.